JPRN-jRCTs031200026已完成3 期
Multicenter, Single blinded Randomized Controlled, Comparative Study to Evaluate the Efficacy and Safety of Favipiravir and Nafamostat Mesilate in Patients with COVID-19 Pneumonia
Shu Okugawa0 个研究点目标入组 45 人开始时间: 2020年5月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 45
研究概览
简要总结
afamostat combined with favipiravir did not improve clinical progression. However, early defervescence and recovery of SpO2 were observed in the combination group.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 75age old（—）
- 性别
- All
入选标准
- •1) Patients who have given written consent to participate in the study
- •2) SARS-CoV-2 test positive
- •3) Patients with pneumonia on chest image
- •4) Patients with fever over 37.5 degrees
- •5) Pregnancy test-negative
排除标准
- •1) Patients with fever over 37.5 degrees for more than 10 days
- •2) Patients having less than 93% of oxygen saturation (SpO2) in without the oxygen administration
- •3) Patients having cardiac dysfunctions such as congestive heart failure, having severe liver dysfunction, and having renal dysfunction requiring dialysis
- •4) Patients having history of gout or currently undergoing treatment of gout or hyperuricemia
- •5) Patients having disorders of consciousness such as disorientation
- •6) Patients who are pregnant or who may be pregnant
- •7)Patients who are suspected to have an infection with a microorganism other than SARS-COV-2, causative organism of pneumonia.
- •8) Patients with hyperkalemia or hyponatremia
- •9) Patients who are considered inappropriate for inclusion in the study by the investigator
研究者
相似试验
已完成
2 期
Efficacy of Combination Therapy of Fluvoxamine and Favipiravir versus Favipiravir Monotherapy to Prevent Severe COVID-19 among Mild to Moderate COVID-19 Patients: Open-label Randomized Controlled Trialconfirmed cases of COVID-19 from SARS-CoV-2 PCRfluvoxamine, COVID-19, SARS-CoV-2, favipiravirTCTR20210615002Chulabhorn Royal Academy296
已完成
4 期
Efficacy Optimizing Research of Lamivudine TherapyCompensated Chronic Hepatitis BNCT01088009Nanfang Hospital, Southern Medical University366
Unknown
3 期
Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19COVID-19NCT04336904Giuliano Rizzardini100
进行中（未招募）
3 期
Phase III clinical trial of favipiravir in early-onset COVID-19 patients with severe risk factorsCOVID-19 patients with risk factors of progression to severe disease onset within 72 hours prior toJPRN-jRCT2041210004Sakurai Tsutomu316
已完成
2 期
Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19Sars-CoV2COVID-19NCT04346628Stanford University149